See more : Escalera Resources Co. (ESCSQ) Income Statement Analysis – Financial Results
Complete financial analysis of Augmedix, Inc. (AUGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Augmedix, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Vama Industries Limited (VAMA.BO) Income Statement Analysis – Financial Results
- Dinglong Culture Co., Ltd. (002502.SZ) Income Statement Analysis – Financial Results
- Axactor ASA (ACR.OL) Income Statement Analysis – Financial Results
- Second Sight Medical Products Inc (EYESW) Income Statement Analysis – Financial Results
- LEVERAGE SHARES PUBLIC LIMITED (NFL1.L) Income Statement Analysis – Financial Results
Augmedix, Inc. (AUGX)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.augmedix.com
About Augmedix, Inc.
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 44.86M | 30.93M | 22.17M | 16.48M | 14.11M | 10.82M |
| Cost of Revenue | 23.33M | 16.98M | 12.16M | 9.69M | 9.43M | 10.03M |
| Gross Profit | 21.53M | 13.95M | 10.01M | 6.79M | 4.68M | 785.92K |
| Gross Profit Ratio | 47.99% | 45.11% | 45.15% | 41.22% | 33.17% | 7.27% |
| Research & Development | 11.18M | 10.15M | 6.68M | 4.52M | 6.98M | 6.96M |
| General & Administrative | 18.44M | 16.89M | 13.76M | 11.57M | 10.86M | 13.15M |
| Selling & Marketing | 10.69M | 9.28M | 7.51M | 4.40M | 3.58M | 3.59M |
| SG&A | 29.13M | 26.18M | 21.27M | 15.97M | 14.44M | 16.75M |
| Other Expenses | 1.00M | -2.08M | 87.00K | -1.91M | 1.05M | 0.00 |
| Operating Expenses | 40.31M | 36.33M | 27.95M | 20.49M | 21.42M | 22.87M |
| Cost & Expenses | 63.63M | 53.30M | 40.10M | 30.18M | 30.85M | 32.90M |
| Interest Income | 1.11M | 245.00K | 15.00K | 10.84K | 6.27K | 2.08M |
| Interest Expense | 2.25M | 2.08M | 2.50M | 1.45M | 2.81M | 0.00 |
| Depreciation & Amortization | 1.10M | 1.53M | 691.00K | 867.00K | 949.01K | 1.59M |
| EBITDA | -17.68M | -21.81M | -14.47M | -12.83M | -14.74M | -21.33M |
| EBITDA Ratio | -39.42% | -72.32% | -80.93% | -83.07% | -104.46% | -197.26% |
| Operating Income | -18.78M | -22.37M | -17.94M | -13.69M | -16.74M | -22.92M |
| Operating Income Ratio | -41.87% | -72.32% | -80.93% | -83.07% | -118.68% | -211.94% |
| Total Other Income/Expenses | -247.00K | -1.97M | 134.00K | -1.91M | -1.76M | -1.24M |
| Income Before Tax | -19.03M | -24.45M | -17.85M | -15.60M | -18.50M | -24.16M |
| Income Before Tax Ratio | -42.42% | -79.04% | -80.54% | -94.67% | -131.12% | -223.41% |
| Income Tax Expense | 145.00K | 2.08M | -691.00K | -867.00K | 3.86M | 0.00 |
| Net Income | -19.17M | -26.53M | -17.16M | -14.74M | -22.36M | -24.16M |
| Net Income Ratio | -42.74% | -85.76% | -77.42% | -89.41% | -158.50% | -223.41% |
| EPS | -0.44 | -0.71 | -0.59 | -2.10 | -26.89 | -20.32 |
| EPS Diluted | -0.44 | -0.71 | -0.59 | -2.10 | -26.89 | -20.32 |
| Weighted Avg Shares Out | 43.95M | 37.42M | 28.91M | 7.03M | 831.59K | 1.19M |
| Weighted Avg Shares Out (Dil) | 43.95M | 37.42M | 28.91M | 7.03M | 831.59K | 1.19M |
Commure Completes Merger with Augmedix
7 AI Penny Stocks to Watch in October
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGX
Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates
Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Augmedix, Inc. – AUGX
Why Is Augmedix (AUGX) Stock Up 150% Today?
Shareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public Shareholders
Augmedix to Join Forces with Commure
Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments
Source: https://incomestatements.info
Category: Stock Reports